Bristol-Myers Squibb said today it launched the Orencia ClickJect autoinjector designed for the self-administration of Orencia to treat moderate to severe rheumatoid arthritis.
The Orencia ClickJect is designed to deliver 125 mg of subcutaneous Orencia through a push button operation with injection confirmation to reduce the possibility of user errors, the company said.
“Today’s launch of the Orencia ClickJect is an example of our continued commitment to offering patients with moderate to severe rheumatoid arthritis a treatment option that may be appropriate for them, now available as an autoinjector. This approval offers more options for healthcare providers and members of the arthritis community to consider when selecting the optimal treatment and administration option for each individual,” U.S. commercial head Chris Boerner said in a press release.
Data from a 48-patient summative study indicated a high level of satisfaction for patients using the Orencia ClickJect, with ratings between 6.4 and 6.9 on a 1-to-7 scale rating comfort, control, ease of use, and confidence of dose, according to the company.
“Rheumatoid arthritis often affects joints in the hand and impairs dexterity.12 Through the new Orencia ClickJect, we are able to offer the proven benefits of Orencia in an accurate dose self-injection and provide an additional option for healthcare providers when selecting treatment options for their patients,” U.S. Orencia medical lead Dr. Sheila Kelly said in prepared remarks.
